NYLI WMC International Rsrch Eq Inv Cl holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
NYLI WMC International Research Equity Investor Class MYINX
- NAV / 1-Day Return 11.58 / +0.70 %
- Total Assets 268.6M
-
Adj. Expense Ratio
1.530%
- Expense Ratio 1.520%
- Distribution Fee Level High
- Share Class Type Front Load
- Category Foreign Large Blend
- Investment Style Large Blend
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 2.04%
- Turnover 109%
USD | NAV as of Jun 13, 2026 | 1-Day Return as of Jun 13, 2026, 12:11 AM GMT+0
Morningstar’s Analysis MYINX
Will MYINX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the MYINX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of MYINX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 21.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Taiwan Semiconductor Manufacturing Co Ltd | 5.49 | 15M | Technology |
Samsung Electronics Co Ltd | 2.54 | 7M | Technology |
ASML Holding NV | 2.28 | 6M | Technology |
Tencent Holdings Ltd | 2.16 | 6M | Communication Services |
SK Hynix Inc | 1.93 | 5M | Technology |
Shell PLC | 1.93 | 5M | Energy |
TotalEnergies SE | 1.71 | 5M | Energy |
British American Tobacco PLC | 1.38 | 4M | Consumer Defensive |
AstraZeneca PLC | 1.18 | 3M | Healthcare |
KBC Groupe NV | 1.15 | 3M | Financial Services |
United States